Thermo Fisher Scientific Inc. $TMO Stock: Nippon Life Global Investors Americas Inc. Increases Stake

Nippon Life Global Investors Americas Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 19,160 shares of the medical research company’s stock after acquiring an additional 4,550 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Thermo Fisher Scientific were worth $12,942,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TMO. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. Corient Private Wealth LP bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $382,547,000. Bank of New York Mellon Corp purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $1,974,561,000. Bank of America Corp DE bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock valued at $1,239,625,000 after acquiring an additional 22,827 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on TMO shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $720.00 price target on shares of Thermo Fisher Scientific in a report on Friday, September 25th. DZ Bank lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Stifel Nicolaus boosted their price target on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Finally, Argus increased their price target on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the company a “buy” rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $689.10.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 76,199 shares of company stock valued at $45,896,780. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $696.78 on Monday. The company’s 50 day moving average is $654.87 and its 200-day moving average is $552.94. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $711.85. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market cap of $257.63 billion, a P/E ratio of 36.75, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the previous year, the firm posted $5.79 EPS. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.